Wegovy and Ozempic are both GLP-1 receptor agonists used to treat obesity and type 2 diabetes. However, there are some differences between the two drugs.

Wegovy (semaglutide) is a once-weekly injection that was approved by the FDA in June 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It is a higher dose of the same medication found in Ozempic. It works by mimicking the effects of the GLP-1 hormone in the body, which helps to regulate blood sugar levels and reduce appetite.

Ozempic (semaglutide) is also a GLP-1 receptor agonist that was approved by the FDA in 2017 for the treatment of type 2 diabetes. It is administered once a week and has been shown to help patients lose weight as a side effect.

While both drugs are similar in their mechanism of action, Wegovy has been shown to be more effective in promoting weight loss than Ozempic. According to a clinical trial, patients who took Wegovy lost an average of 17.4% of their body weight, while those who took Ozempic lost an average of 10.8% of their body weight.

Another difference between the two drugs is their cost. According to GoodRx [2], the average retail price for a 4-week supply of Wegovy is around $1,300, while the average retail price for a 4-week supply of Ozempic is around $900.

In conclusion, Wegovy and Ozempic are both GLP-1 receptor agonists used to treat obesity and type 2 diabetes. However, Wegovy has been shown to be more effective in promoting weight loss and is more expensive than Ozempic. Patients should consult with their healthcare provider to determine which medication is best for their individual needs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.goodrx.com/classes/glp-1-agonists/wegovy-vs-ozempic
[3] https://www.uchealth.org/today/wegovy-vs-ozempic-the-truth-about-new-weight-loss-drugs/